The number of low and intermediate-risk prostate cancer patients undergoing active surveillance in place of aggressive treatment has tripled to quadrupled over the last 20 years.

UCSF Urology has been ranked #10 in the nation and #1 in California in the 2026-2027 U.S. News & World Report Best Hospitals specialty rankings. This recognition is one of several recent distinctions ...

Image The UCSF Department of Urology is pleased to announce the appointment of Rishi R. Sekar, MD, MSc, as the new associate program director of the Urologic Oncology Fellowship Program. Dr. Sekar suc...

Image The UCSF Department of Urology is pleased to announce the appointment of David T. Tzou, MD, as co-program director of the Endourology Fellowship Training Program, where he will serve alongside D...

University of California, San Francisco is hiring. Apply now!

The RECIPROCAL trial is seeking to enroll approximately 1,500 participants with prostate cancer nationwide.

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

After years of worrying that running or sneezing would leave me needing fresh underwear, a quick, minimally invasive procedure changed my life

An article in GU Oncology Now highlights how UCSF Department of Urology researchers in The Chu Lab have discovered new details about how prostate cancer cells control a protein called STEAP1, which is...

Where people live, work, and play can significantly impact their health and health care provision, including cancer screening, prevalence, and mortality outcomes, but how do we know which factors shou...

YouTube video by ASPI: Active Surveillance Patients International

UCSF Urology has named Sima P. Porten, MD, MPH as Chief of Urologic Oncology, a role that recognizes her exceptional clinical expertise, research leadership, and long-standing commitment to advancing ...

PGY1, urology resident, Sudarshan V. Srirangapatanam, MD, received the 2024-25 ZSFG Krevans Award for his excellent performance during his intern year at the Priscilla Chan and Mark Zuckerberg San Fra...

Presentation by Dr. Ashwin Balakrishnan, Dr. Farnoosh Nik-Ahd and Dr. Adrian Fernandez

Dr. Chu highlights how PSMA PET is transforming perioperative prostate cancer care, including improving surgical precision.

A cancer drug developed ten years ago at UCSF can also put the brakes on one of prostate cancer's deadliest molecular tricks.

UCSF scientists discover how cancer cells hijack the protein factory of the cell to churn out MYC protein, the driver of 70% of all cancers.

Rates of advanced prostate cancer in California rose significantly in the decade since doctors stopped routinely screening all men. A UCSF study reinforces the need for screening that can identify pot...